Companies
/Healthcare
TG Therapeutics Inc
$55.72
â–² $0.69 (+1.25%) today
Markets closed · 7:41pm ET
Today · % change
Fundamentals
Market Cap
$8.4B
P/E Ratio
20.2
Profit Margin
55.2%
Revenue (TTM)
$799.5M
EPS (TTM)
$2.72
52-Week Range
$27 – $59
Street Target
$69.71
About TG Therapeutics
TG Therapeutics Inc is a biopharmaceutical company focused on creating innovative treatments for B-cell mediated diseases, such as multiple sclerosis and various forms of lymphoma. It markets BRIUMVI, a treatment for multiple sclerosis, and has a pipeline of potential therapies, including Umbralisib for lymphoma and TG-1701, a targeted cancer treatment. With a commitment to advancing care, TG Therapeutics collaborates with several partners to enhance its research and development efforts. Founded in 1993, the company is headquartered in Morrisville, North Carolina.